American medicine can tell you the average time to diagnose Cushing's syndrome is 34 months and 4.6 doctors. What it can't tell you is why the specialist whose entire domain touches nearly every other system in the body isn't paid, trained, or expected to look for the connection first.
Three weeks ago, this newsletter documented why your specialists don't talk to each other: fee-for-service billing doesn't pay anyone to coordinate, and medical training still produces doctors who think in terms of organs rather than systems. That piece focused on the mechanics of why nobody connects the dots. This one is about a sharper version of the same failure.
Here's the sharper version: an endocrinologist doesn't just treat one gland. The endocrine system regulates blood sugar, blood pressure, sleep, weight, mood, and reproduction — arguably, no other specialty's domain touches as many other systems in the body. A specialist trained in that domain, seeing a patient with type 2 diabetes, high blood pressure, sleep apnea, and unexplained weight gain, has everything needed to recognize a pattern and ask what single thing might be driving all four — a question a well-trained endocrinologist, or anyone in medicine, is positioned to answer. And yet endocrinology is one of the lowest-paid specialties in American medicine — third from the bottom, according to Medscape's 2025 Physician Compensation Report, at roughly $290,600 a year, well below most other specialties. There's no financial signal anywhere in the system rewarding the kind of cross-system thinking this case actually needs. Instead, the default is to treat each piece on its own and refer out whatever doesn't fit in-lane neatly. That's not a training gap or a 15-minute appointment problem alone. It's a system that has decided ownership of the whole patient stops at the border of each specialty — even in the one specialty built, more than almost any other, to understand how the body's systems interact.
That failure has a second, related layer, and it's important not to collapse the two into one claim: the professional bodies that represent these same specialists could also be the loudest voice in the country demanding research into what's driving the disease burden they see every day — plastics-derived chemicals disrupting hormonal systems among them. Instead, their lobbying budgets go almost entirely toward reimbursement, scope-of-practice turf wars, and prior authorization paperwork. That's a separate, additional silence, not an explanation for any single patient's diagnosis — and patients, meanwhile, spend years being handed from specialist to specialist while both problems go unaddressed.
The Diagnostic Delay Isn't a Feeling — It's a Documented Number
Patients living through a slow diagnosis often describe it as feeling dismissed, minimized, or shuffled along. It turns out that's not a subjective impression — it's a quantified, published pattern, and the numbers are worse than the general "fragmented care" statistics this newsletter already covered.
A meta-analysis covering 5,367 patients with Cushing's syndrome — a disease caused by chronic excess cortisol, often from a tumor on the adrenal or pituitary gland, that in turn commonly presents as some combination of high blood pressure, type 2 diabetes, sleep apnea, and weight gain — found a mean time to diagnosis of 34 months across all subtypes. Other published research on the same disease found that it takes more than 4 years from symptom onset to diagnosis in a meaningful share of patients, with an average of 4.6 physicians consulted along the way. A global patient survey found that 48.7% of patients with Cushing's waited more than two years for a diagnosis, and 30.3% waited more than three years. Researchers attribute the delay to "the nonspecific nature of subjective symptoms" and "notorious challenges in the interpretation of diagnostic testing" — in plainer terms, each individual symptom looks treatable on its own, so it gets treated on its own, by whichever specialist happens to be looking at it that year.
This is precisely the pattern that this newsletter's earlier piece described: fee-for-service billing pays for treating the symptom in front of you, not for asking whether five "unrelated" symptoms in the same patient might share a single cause. That piece is named the financial mechanism. This one is about what happens next — because it would be one thing if the profession's own advocacy arms were fighting to fix it.
Nobody Owns Making the Next Referral Happen Faster
There's a specific failure within that 34-month number worth naming on its own: even after a doctor suspects something is genuinely wrong, the system has no mechanism to ensure the next appointment happens quickly. Research on the referral process itself finds that residents and early-career physicians consistently report inadequate training in how to triage and escalate referrals — the decision of "this needs to happen soon" versus "this can wait" is left to informal judgment rather than a taught skill. Referral notes themselves frequently arrive at the receiving specialist's office incomplete, missing key clinical details, or failing to convey the urgency the referring doctor may have actually felt. And structurally, referring physicians and specialists routinely work inside electronic health record systems that don't talk to each other, meaning neither side can see the full lifecycle of a referral once it leaves their hands — nobody is accountable for whether it actually moved quickly, because nobody owns the process from end to end.
That's a different problem than a doctor simply not caring enough to push. It's a system where "advocating to get a patient seen sooner" isn't a billable action, isn't a trained skill, and isn't tracked by anyone once the referral is sent — which means it depends entirely on an individual physician's unpaid, unmeasured initiative, every single time.
What the Doctors' Own Lobbyists Are Actually Fighting For
The American Medical Association spent nearly $25 million on federal lobbying in 2024. Its current advocacy priorities, published on its own site, center on physician workforce shortages, pharmacy-benefit-manager transparency, scope-of-practice disputes with nurse practitioners and other providers, prior authorization reform, and Medicare payment rates. The Endocrine Society — the specialty body most directly positioned to speak on exactly the kind of hormonal, multi-system disease this piece opened with — lists its top 2025–2026 priorities as opposing federal rules that threaten NIH research funding, reauthorizing the Special Diabetes Program, and capping insulin costs through the INSULIN Act. Its most recent tangible win, as of this July, is a new CMS "Medicare Bridge Program" expanding Part D coverage of GLP-1 weight-loss drugs for a $50 copay — the Society's own advocacy update calls it a direct result of the Society having "urged Congress and the administration to expand access to GLP-1 medications." That's the shape of the whole pattern in miniature: real, hard-won advocacy energy, aimed at paying for more downstream treatment, not at funding research into what's driving the underlying disease upstream.
These are not frivolous priorities. Insulin affordability matters. Physician shortages matter. But notice what's absent from either organization's own published agenda: nothing on environmental exposure to endocrine-disrupting chemicals, nothing on food quality or agricultural chemical exposure, nothing pushing Congress to fund or mandate research into what's driving the underlying disease burden further upstream than a prescription pad can reach. The two organizations best positioned to make that case professionally — with the credibility and the membership base to be heard — are, by their own public record, not making it.
That's not an accusation that individual doctors don't care. It's a description of where two large, well-funded professional associations choose to spend their political capital, documented from their own published materials, and it happens to line up exactly with what gets a physician paid versus what doesn't.
The Science That's Not Getting Lobbied For
To be clear about what this section is and isn't arguing: nothing here explains any single patient's Cushing's diagnosis, which is a distinct, tumor-driven condition requiring its own workup — that's the domain-ownership failure described above, and it's a separate problem from the one below. What follows is about a second, additional silence: the science connecting environmental chemical exposure to obesity, type 2 diabetes, and metabolic syndrome — a massive and growing share of the disease burden American doctors treat every single day, Cushing's or not — is not fringe or speculative. It's a growing, published body of peer-reviewed research.
Plastics contain more than 16,000 distinct chemicals, and a meaningful subset of them are documented endocrine disruptors. Bisphenol A (BPA), still common in plastic packaging and resins, mimics estrogen and disrupts thyroid hormone regulation, with published research connecting it to obesity, diabetes, and cardiovascular disease. Phthalates function as what researchers call "obesogens" — they interfere with the liver receptors that regulate glucose, fatty acid, and cholesterol metabolism, and epidemiological studies link phthalate exposure directly to diabetes risk. Microplastics themselves act as carriers for these same chemicals, effectively delivering hormone-disrupting compounds into the body through an exposure pathway that didn't meaningfully exist a few generations ago. None of this is this newsletter's interpretation — it's the summarized findings of multiple peer-reviewed reviews on metabolic-disrupting chemicals, published in journals including Environmental Endocrinology and the American Journal of Physiology.
Worth being precise about where the evidence is weaker: one specific version of this argument — that pesticide residue in conventionally raised, grain-fed beef is itself a meaningful health risk — does not hold up as well under the same scrutiny. The most-cited feed-residue research on glyphosate found that concentrations in muscle tissue were below the limit of detection under typical feeding conditions, and that there were no discernible health differences between products from animals fed glyphosate-treated crops and those fed untreated crops — worth noting plainly that this particular study was authored by four Bayer CropScience scientists, Bayer being the manufacturer of glyphosate-based herbicides. That's the same kind of sponsor-authored research this piece just spent a whole section warning readers to read skeptically, and it deserves the same skepticism here, not a pass. Even granting that skepticism, it's notable that the industry's own commissioned science didn't find a signal worth manufacturing — an independent 2021 review from Aarhus University, published in the journal Animal, covers the same feed-residue question without that conflict, and is the more defensible citation for readers who want to check this claim themselves. Either way, this doesn't mean the broader "food and chemical environment" concern is wrong — it means this particular thread rests on a compromised primary source, and a piece making the broader case shouldn't lean on it without saying so.
The stronger case is the plastics-and-packaging one, and it's not obscure. It's been published for years. The organizations representing the doctors who treat diabetes, obesity, and metabolic syndrome every day have access to the same literature that this newsletter just cited. What they've chosen to spend lobbying dollars on instead is documented above.
The Money Behind What Actually Gets Prescribed
There's a second, related silence worth naming: even when a root cause does get identified, what a doctor is likely to reach for next isn't independent of who's paying for their attention.
Drug and device manufacturers reported $2.6 billion in direct payments to more than 665,000 physicians in 2025 alone, through the federally mandated Open Payments system — plus another $1.3 billion to teaching hospitals and non-physician practitioners, for a combined $3.9 billion, up 18.4% from the previous year. A telling detail inside that number: 34% of those payment dollars were categorized as "not product-related" in 2025, up from 21% the year before — meaning even the payments manufacturers are legally required to disclose are increasingly labeled in ways that make them harder to trace back to a specific drug being promoted.
That money matters because of what independent, peer-reviewed research consistently finds about industry-funded clinical trials. A Cochrane systematic review covering 75 studies found industry-sponsored drug and device trials were more likely to report favorable efficacy results (risk ratio 1.27) and favorable overall conclusions (risk ratio 1.34) than trials funded from other sources. A separate analysis of 332 medical and surgical trials found industry funding was associated with a statistically significant pro-industry result at nearly twice the rate of independently funded trials (odds ratio 1.9). And in a meta-research study focused specifically on monoclonal antibody drug trials, 78.5% of the ones fully funded by the pharmaceutical industry reached conclusions favoring the sponsor's drug. Researchers who study this bias point to specific mechanisms: choosing comparison doses that flatter the sponsor's drug, selectively publishing favorable results while quietly withholding unfavorable ones, and framing research questions so that the technically true answer is also the most flattering one. This is the evidence that a huge share of prescribing decisions ultimately rests on.
None of this requires assuming fraud. It describes a testing and marketing system in which the party funding most of the research also has a direct financial stake in what that research finds — a structural conflict, when aggregated, that shapes outcomes in a statistically consistent and measurable direction.
What "Not Properly Tested" Actually Means, More Precisely
It's worth being exact here rather than reaching for the strongest possible version of this claim. The FDA's accelerated approval pathway — used mainly for serious diseases like cancer, where patients often don't have years to wait for a full confirmatory trial — is a known, publicly debated tradeoff: faster access in exchange for accepting more uncertainty about long-term benefit, with a confirmatory trial required afterward. It is not secretly untested medicine being slipped past regulators.
But the trade-off has a real cost, and the data on it is concerning in its own right. By August 2024, 200 oncology indications had been granted accelerated approval; of the 167 old enough to have reached a resolution one way or the other, 31 — 19% — were later withdrawn, primarily because the required confirmatory trials failed to verify the clinical benefit the accelerated approval assumed, or because new safety concerns emerged. (The remaining 34 of that 167 were still ongoing accelerated approvals awaiting resolution; the other 33 of the full 200 were too recently approved to be assessed at all.) Specific examples: the targeted cancer drug idelalisib (Zydelig) won accelerated approval in 2014, had fatal-adverse-event risks flagged by regulators as early as 2016, and didn't have two of its indications formally withdrawn until May 2022 — eight years after approval, and six years after the safety signal first appeared (it remains on the market today for a different, still-approved use); a sickle cell disease gene therapy was pulled from markets worldwide in 2024 after data showed a higher rate of death and serious complications in treated patients; a multiple myeloma drug lost its approval in February 2023 after confirmatory trials failed to show it actually worked. In each case, patients were taking these drugs, in some cases for years, before the evidence caught up to the approval.
corporatocracy (noun) — a system where the professional associations best positioned to demand upstream answers instead spend their lobbying budgets on the reimbursement fights that pay their members, while the published science on what's actually driving the disease burden sits unlobbied-for in a journal nobody in Washington is being asked to read.
curated control (noun) — a system that will spend 34 months methodically ruling out one organ system at a time, and $25 million lobbying dollars protecting how doctors get paid, before anyone is structurally rewarded for connecting what they're seeing to a bigger picture — whether that's one patient's undiagnosed tumor or a population-wide chemical exposure nobody in the specialty is required to study.
What This Doesn't Mean
This isn't a claim that individual physicians are lazy, corrupt, or indifferent to their patients — the doctors doing the actual diagnosing are working inside a system of appointment lengths, billing codes, and professional incentives none of them personally designed. It's also not a claim that every drug on the market is inadequately tested, or that all industry-funded research is invalid — most of modern medicine's real gains came through exactly that funding pipeline. The claim, specifically and only, is this: the organizations with the credibility, membership, and lobbying infrastructure to make upstream causation a national political priority have chosen, by their own published record, not to spend that capital there, and the diagnostic and financial patterns documented above are what that choice looks like from the patient's side of the exam table.
What You Can Actually Do About It
- If a specialist can't explain how your condition might connect to your other diagnoses, ask directly: "What else could explain this cluster of symptoms together?" That question costs nothing and shifts the burden of ruling out a shared cause back to the visit, rather than leaving it to a future referral.
- Ask explicitly whether a referral is urgent or routine, and ask your doctor to say so in writing on the referral itself — since referral notes are frequently the only signal a receiving specialist's office has, and vague ones default to the back of the queue.
- Request your own records and imaging directly rather than waiting for one office to send them to the next. Fragmented EHR systems mean the next doctor may never see your full history unless you're the one who closes that gap.
- If you're a patient advocacy group member or belong to a condition-specific nonprofit, ask directly whether that organization lobbies on environmental or dietary causation research funding — many don't, and asking is often the first step toward getting one added to an agenda.
Call to Action
Every mechanism documented in this piece has a real address it can be pushed at — a professional association with a stated legislative agenda, a federal agency with a specific funding stream, a committee with actual jurisdiction. Here's specifically where to direct that:
- Contact the American Medical Association and the Endocrine Society directly and ask them to add funding for environmental endocrine-disruptor research and food-quality reform to their published federal lobbying priorities. Both organizations solicit member and public input on their advocacy agendas; neither currently lists this among its stated priorities, and that's a documented, checkable fact, not a guess.
- Contact your member of Congress and ask them to support increased NIH funding specifically earmarked for environmental endocrine-disruptor research, rather than general NIH funding increases that professional societies already lobby for — the distinction matters, since general funding doesn't guarantee this specific research gets prioritized inside the agency.
- Contact the FDA and ask directly what percentage of accelerated-approval confirmatory trials are completed within the required timeline, given that some drugs, like the example in this piece, have carried unresolved safety questions for years before their indications were finally withdrawn.
- If your condition took years to diagnose, consider filing that experience with your relevant patient advocacy nonprofit's public comment or testimony process — HHS, FDA, and congressional committees periodically solicit exactly this kind of patient-experience testimony, and diagnostic-delay data of the kind cited in this piece gets stronger, not weaker, with more individually documented cases behind it.
Sources
Chen S, et al. Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5,367 Patients, Journal of Clinical Endocrinology & Metabolism.
Cushing's Disease News/patient survey coverage. Delayed Diagnosis May Lead to Persistent Symptoms in Cushing's — Survey: Nearly Half of Patients Wait Over 2 Years for Diagnosis.
American Medical Association. Advocacy priorities and 2024 lobbying expenditure, ama-assn.org and OpenSecrets AMA lobbying profile.
Endocrine Society. Advocacy Update: July 2026 and related Endocrine News advocacy coverage, endocrinenews.endocrine.org.
Oxford Academic, Environmental Endocrinology. Microplastics, nanoplastics, and plastic chemicals: applying the key characteristics of metabolism disrupting agents shows reason for concern.
American Journal of Physiology-Endocrinology and Metabolism. Endocrine disruptors in plastics alter β-cell physiology and increase the risk of diabetes mellitus.
PMC. The Role of Endocrine Disruptors Bisphenols and Phthalates in Obesity: Current Evidence, Perspectives and Controversies.
Vicini JL, Reeves WR, Swarthout JT, Karberg KA. Glyphosate in livestock: feed residues and animal health, Journal of Animal Science, 2019;97(11):4509-4518 — authors are Bayer CropScience employees; disclosed in this piece as a sponsor-authored source.
Sørensen MT, Poulsen HD, Katholm CL, Højberg O. Review: Feed residues of glyphosate – potential consequences for livestock health and productivity, Animal, 2021;15(1):100026 — independent academic source (Aarhus University), no industry affiliation.
CMS Open Payments program, 2025 reporting year; Medscape coverage, Manufacturers Report $2.6 Billion in Open Payments to Physicians.
Cochrane Database of Systematic Reviews. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome (MR000033), 2017 — 75-study systematic review and meta-analysis.
Bhandari M, et al. Association Between Industry Funding and Statistically Significant Pro-Industry Findings in Medical and Surgical Randomized Trials, CMAJ, 2004;170(4):477-80.
SciELO/PMC. Conclusions of clinical trials assessing monoclonal antibodies and sponsored by pharmaceutical industry: a meta-research study.
PMC. The association of funding source on effect size in randomized controlled trials: 2013–2015 — a cross-sectional survey and meta-analysis.
eClinicalMedicine (The Lancet). Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study.
Malpractice by Design: Why Your Specialists Don't Talk to Each Other — this newsletter's prior Dispatch, companion piece covering the fee-for-service and medical-training mechanisms behind the same diagnostic-delay pattern documented here.